



Evidence-based recommendations for the use of permanent CVADs in paediatric oncology

Simon et al.
Society for Paediatric Oncology and Haematology
(Gesellschaft für Pädiatrische Onkologie und Hämatologie, GPOH) 2018

21.4 Taurolidine for the prophylaxis against CVAD-related infections

Lock solutions containing taurolidine are recommended for the prevention of CVAD related infections (Cat. IB).

Taurolidine-containing lock solutions are also recommended for paediatric cancer patients on cyclised (home) parenteral nutrition if an infusion-free interval of at least 4 hours is available (Cat. IB for patients on home parenteral nutrition).

23.6.3 Taurolidine lock for adjuvant therapy

Taurolidine (e.g. 1.35 % taurolidine, 4 % citrate) can be used as an adjuvant measure during systemic treatment with antibiotics (Cat. II). The minimal dwell time in the catheter lumen is 4 hours.

23.6.4 Urokinase lock as adjuvant therapy

Results of in-vitro experiments, studies on prophylaxis, and observational studies support the adjuvant use of urokinase for gram-positive catheter infections since these are often associated with blood clotting within the CVAD (Cat. II).

(Translated from German)